Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
A GHRH analogue with a Drug Affinity Complex — binds albumin covalently, radically extending its half-life.
Size: 10 mg
No published analyses yet.
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 1 mg (1000 mcg) subcutaneously, once weekly | Starting dose |
| Maintenance | 2 mg once weekly | Increase if needed |
| Split regimen | 2 mg per week, divided into 2 injections (1 mg each) | Maximum in this schedule |
Share your experience
No reviews yet. Tell others what you think of this product.
CJC-1295 with DAC is a synthetic growth-hormone-releasing-hormone (GHRH) analogue that has become one of the go-to tools in GH-axis research protocols. Built on the GRF(1-29) fragment, four amino-acid substitutions protect the molecule from DPP-4 cleavage, while the DAC (Drug Affinity Complex, a maleimide group) binds covalently to plasma albumin — the distinction from CJC-1295 without DAC, and what extends the half-life from minutes to days in research models.
Studied for raising baseline GH and IGF-1 while preserving the pulsatile character of secretion. It acts through the GHRH receptor — a pathway distinct from secretagogues such as GHRP-6.
Supplied as a lyophilized powder; every batch is assayed by HPLC.
Buy 2, get the 3rd free
The set contains two vials of 10 mg.
20 mg: Best value · Save ≈ $6.33
